NCT03862105 is a NA clinical trial of Mobile Health app tool - Twistle in Invasive Bladder Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Who is sponsoring NCT03862105?

NCT03862105 is sponsored by UNC Lineberger Comprehensive Cancer Center.

What drugs are being tested in NCT03862105?

Interventions in NCT03862105: Mobile Health app tool - Twistle.

What condition does NCT03862105 study?

NCT03862105 studies Invasive Bladder Cancer.

Is NCT03862105 still recruiting?

NCT03862105 is currently completed. Last updated 12 June 2020.

Last reviewed 2020-06-12 · How we verify

NCT03862105

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer

Completed NA Last updated 12 June 2020

What this trial tests

NA trial testing Mobile Health app tool - Twistle in Invasive Bladder Cancer in 33 participants. Completed in 27 April 2020.

Timeline

25 March 2019

Primary endpoint
27 April 2020

27 April 2020

Quick facts

Lead sponsor	UNC Lineberger Comprehensive Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	33
Start date	25 March 2019
Primary completion	27 April 2020
Estimated completion	27 April 2020
Sites	1 location across United States

Drugs / interventions tested

Mobile Health app tool - Twistle

Conditions studied

Invasive Bladder Cancer — all drugs for Invasive Bladder Cancer →

Sponsor

UNC Lineberger Comprehensive Cancer Center — full company profile →

Who can join

Adults 18 to 100, any sex, with Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study that involves human subjects undergoing cystectomy surgery for bladder cancer, testing the utilization of a mobile health app that promotes postoperative patient engagement, along with provider monitoring and care. The aim of this pilot study is to assess feasibility and acceptability of an Internet-based mobile health tool following cystectomy discharge. Objectives will be met by assessing weekly adherence, determining acceptability of mobile health questions post-surgery by patients and providers, and by obtaining participant feedback regarding the tool. Complications, re-admissions, and resource utilization will also be monitored throughout the study. The hypothesis is that an mobile health intervention that tracks PROs, provides educational content, and allows real-time feedback via internet-enabled devices has the potential to improve the quality of care delivery and overall patient experience following surgery by decreasing resource utilization and improving symptom control and communication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Invasive Bladder Cancer

Currently open trials in the same condition.

NCT02560636 — Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer · Phase 1 · active not recruiting

Other UNC Lineberger Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06656936 — The PharmFIT Study · NA · not yet recruiting
NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT · not yet recruiting
NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors · not yet recruiting
NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03862105 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
Last refreshed: 12 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03862105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing